Abiopharma

🔍 PYSZCZYMUKA GREG (Executive)

Company: Evoke Pharma Inc (EVOK)

Report Date: 2025-12-17

Detailed Transactions and Holdings:

• Sold 5,833 shares of Stock Option (Right to Buy) at $5.26 per share (Derivative)
  Date: 2025-12-17 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 1,155 shares of Stock Option (Right to Buy) at $3.453 per share (Derivative)
  Date: 2025-12-17 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
• F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.